By Fineline Cube 
China-based Tonghua Dongbao Pharmaceuticals (SHA: 600867) has announced a significant milestone in its clinical development program with the first patient dosing in the Phase II clinical study of THDBH120. This study is designed to assess the efficacy and safety of the GLP-1/GIP dual-targeted receptor agonist in weight loss applications.
THDBH120 Development Background
THDBH120 is being developed as a therapeutic option for both type 2 diabetes (T2D) and obesity. The drug previously initiated a Phase Ib study in June 2024, focusing on its hypoglycemic effects. The progression to Phase II for weight loss indications marks a strategic expansion of its potential therapeutic applications.
Market Context and Precedent
This development comes in the wake of Eli Lilly’s success with its GLP-1/GIP dual-targeted receptor agonist Mounjaro (tirzepatide), which has been approved for blood sugar control in T2D in the US, European Union, and China. Notably, the weight loss version of Mounjaro, marketed as Zepbound, received regulatory approval in the US in November of the previous year. Tonghua Dongbao’s advancement of THDBH120 into Phase II for weight loss aligns with the growing interest in dual-target therapies for metabolic disorders, following the positive market reception of similar agents.-Fineline Info & Tech